CONTINUATION PAGES TO SCHEDULE 13D
This amendment to Schedule 13D is being filed by AI Day1 LLC (“AI Day1”), Access Industries Holdings LLC (“AIH”), Access Industries Management, LLC (“AIM”) and Len Blavatnik (collectively, the “Reporting Persons”, and each, a “Reporting Person”), in respect of the common stock, par value $0.0001 per share (the “Common Stock”), of Day One Biopharmaceuticals, Inc. (the “Issuer”).
The Schedule 13D (the “Schedule”) filed with the SEC on June 9, 2021 is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 1. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended, and refers only to information that has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule.
Item 3 | Source and Amount of Funds or Other Considerations |
The disclosure in Item 3 is hereby supplemented by adding the following at the end thereof:
On January 18, 2022, AI Day1 purchased 43,429 shares of Common Stock at a weighted average price of $14.26161 per share in open market transactions.
On January 19, 2022, AI Day1 purchased 58,818 shares of Common Stock at a weighted average price of $14.6992 per share in open market transactions.
On January 20, 2022, AI Day1 purchased 4,615 shares of Common Stock at a weighted average price of $14.72933 per share in open market transactions.
On June 17, 2022, AI Day1 purchased 1,200,000 shares of Common Stock in the Issuer’s public offering at the public offering price of $15.00 per share.
AI Day1 funded the purchases described above using capital contributed from affiliated entities, which funded that capital using cash on hand.
Item 5 | Interest in Securities of the Issuer |
The disclosure in Item 5 is hereby amended and restated as follows:
(a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of common stock (including but not limited to footnotes to such information) are incorporated herein by reference.
The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of common stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.
1 | These shares were purchased in multiple transactions at prices ranging from $14.05 to $14.53, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range. |
2 | These shares were purchased in multiple transactions at prices ranging from $14.16 to $14.75, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range. |
3 | These shares were purchased in multiple transactions at prices ranging from $14.60 to $14.75, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range. |